2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Ashish R. Panchal, Katherine M. Berg, Peter J. Kudenchuk, Marina Del Rios, Karen G. Hirsch, Mark S. Link, Michael C. Kurz, Paul S. Chan, José G. Cabañas, Peter T. Morley, Mary Fran Hazinski, Michael W. Donnino

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

Original languageEnglish (US)
Pages (from-to)e740-e749
JournalCirculation
Volume138
Issue number23
DOIs
StatePublished - Dec 4 2018

Fingerprint

Anti-Arrhythmia Agents
Cardiopulmonary Resuscitation
Emergency Medical Services
Ventricular Fibrillation
Ventricular Tachycardia
Heart Arrest
Guidelines
Shock
Amiodarone
Lidocaine

Keywords

  • advanced cardiac life support, adult
  • AHA Scientific Statements
  • anti-arrhythmia agents
  • cardiopulmonary resuscitation
  • heart arrest
  • tachycardia, ventricular
  • ventricular fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. / Panchal, Ashish R.; Berg, Katherine M.; Kudenchuk, Peter J.; Del Rios, Marina; Hirsch, Karen G.; Link, Mark S.; Kurz, Michael C.; Chan, Paul S.; Cabañas, José G.; Morley, Peter T.; Hazinski, Mary Fran; Donnino, Michael W.

In: Circulation, Vol. 138, No. 23, 04.12.2018, p. e740-e749.

Research output: Contribution to journalArticle

Panchal, Ashish R. ; Berg, Katherine M. ; Kudenchuk, Peter J. ; Del Rios, Marina ; Hirsch, Karen G. ; Link, Mark S. ; Kurz, Michael C. ; Chan, Paul S. ; Cabañas, José G. ; Morley, Peter T. ; Hazinski, Mary Fran ; Donnino, Michael W. / 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. In: Circulation. 2018 ; Vol. 138, No. 23. pp. e740-e749.
@article{81aadaaaa52f43cb9167e370a66d72c5,
title = "2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care",
abstract = "Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.",
keywords = "advanced cardiac life support, adult, AHA Scientific Statements, anti-arrhythmia agents, cardiopulmonary resuscitation, heart arrest, tachycardia, ventricular, ventricular fibrillation",
author = "Panchal, {Ashish R.} and Berg, {Katherine M.} and Kudenchuk, {Peter J.} and {Del Rios}, Marina and Hirsch, {Karen G.} and Link, {Mark S.} and Kurz, {Michael C.} and Chan, {Paul S.} and Caba{\~n}as, {Jos{\'e} G.} and Morley, {Peter T.} and Hazinski, {Mary Fran} and Donnino, {Michael W.}",
year = "2018",
month = "12",
day = "4",
doi = "10.1161/CIR.0000000000000613",
language = "English (US)",
volume = "138",
pages = "e740--e749",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - 2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest

T2 - An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

AU - Panchal, Ashish R.

AU - Berg, Katherine M.

AU - Kudenchuk, Peter J.

AU - Del Rios, Marina

AU - Hirsch, Karen G.

AU - Link, Mark S.

AU - Kurz, Michael C.

AU - Chan, Paul S.

AU - Cabañas, José G.

AU - Morley, Peter T.

AU - Hazinski, Mary Fran

AU - Donnino, Michael W.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

AB - Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.

KW - advanced cardiac life support, adult

KW - AHA Scientific Statements

KW - anti-arrhythmia agents

KW - cardiopulmonary resuscitation

KW - heart arrest

KW - tachycardia, ventricular

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=85058077460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058077460&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000613

DO - 10.1161/CIR.0000000000000613

M3 - Article

C2 - 30571262

AN - SCOPUS:85058077460

VL - 138

SP - e740-e749

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 23

ER -